8-K/A: Dentsply Sirona Corrects Filing, Reaffirms 2026 Outlook

DENTSPLY SIRONA Inc. filed an amendment to its Form 8-K to correct an EDGAR description tag, confirming its second quarter 2026 financial results and reiterating its full-year outlook.

Summary

• DENTSPLY SIRONA Inc. filed an amendment (Form 8-K/A) to correct a previous Form 8-K filing from August 6, 2026. The amendment solely corrects the EDGAR description tag from 'Current report, Item 9.01' to 'Current report, Items 2.02 and 9.01'.
• The original filing reported financial results for the second fiscal quarter ended June 30, 2026.
• Net sales for Q2 2026 were $898 million, a decrease of 4.1% compared to $936 million in Q2 2025.
• GAAP gross margin improved to 54.9% in Q2 2026 from 52.4% in Q2 2025.
• GAAP diluted earnings per share was $0.18 in Q2 2026, compared to a loss of ($0.22) in Q2 2025.
• Adjusted gross margin was 56.4%, adjusted EBITDA margin was 21.3%, and adjusted EPS was $0.52 in Q2 2026, consistent with Q2 2025 adjusted EPS.
• The company reiterated its 2026 outlook for net sales between $3.5 billion and $3.6 billion, and adjusted EPS between $1.40 and $1.50.
• Operating cash flow was $99 million in Q2 2026, up from $48 million in Q2 2025, and free cash flow was $55 million, up from $16 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive sentiment, primarily due to the correction of a filing error and the reiteration of guidance, despite a slight year-over-year revenue decline.

Positives

• GAAP gross margin improved to 54.9% in Q2 2026 from 52.4% in Q2 2025.
• GAAP diluted earnings per share turned positive at $0.18 in Q2 2026, compared to a loss of ($0.22) in Q2 2025.
• Operating cash flow significantly increased to $99 million in Q2 2026 from $48 million in Q2 2025.
• Free cash flow more than tripled to $55 million in Q2 2026 from $16 million in Q2 2025.
• The company reiterated its full-year 2026 outlook for net sales and adjusted EPS.
• 1.3 million shares of common stock were repurchased for approximately $12 million in Q2 2026.

Negatives

• Reported net sales decreased by 4.1% to $898 million in Q2 2026 compared to $936 million in Q2 2025.
• Constant currency sales decreased by 6.3% in Q2 2026.
• Adjusted EBITDA decreased slightly to $190 million in Q2 2026 from $197 million in Q2 2025.
• Total assets decreased from $5,429 million at December 31, 2025, to $5,204 million at June 30, 2026.

Risks

• The filing references 'Forward-Looking Statements and Associated Risks' and directs readers to Part I, Item 1A, 'Risk Factors' of the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q for a discussion of risks and uncertainties.
• Specific risks mentioned in the forward-looking statements section include numerous assumptions, risks, uncertainties, and other factors that could cause actual results to differ materially from those described.

Future Outlook

The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50. The benefits of refunds for tariffs are not included in the outlook for 2026 adjusted EPS.

Management Comments

• "2026 continues to be a year of decisive action as we execute our Return-to-Growth Action Plan," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona.
• "We are making meaningful progress in our highest priority areas, including strengthening and expanding our distributor relationships, realigning our sales teams, and reinvesting in the business."
• "Our second quarter results were in line with expectations and we continue to strengthen the financial foundation of the company."
• "As our work gains traction, we remain focused on executing our strategy with discipline to drive sustained, profitable growth."

Industry Context

StockSavvy.ai notes that Dentsply Sirona operates in the highly competitive dental products and technologies market. The company's focus on a 'Return-to-Growth Action Plan' and reinvestment in the business suggests a strategic effort to navigate market dynamics and enhance its competitive position against other major players in the dental industry.

Stakeholder Impact

• Shareholders: Reiteration of 2026 outlook and improved cash flow may be viewed positively, while the slight year-over-year revenue decline could be a concern.
• Employees: The 'Return-to-Growth Action Plan' and 'realigning our sales teams' may imply organizational changes.
• Suppliers/Creditors: Improved operating cash flow and free cash flow could positively impact liquidity and ability to meet obligations.

Next Steps

• Continue executing the 'Return-to-Growth Action Plan'.
• Strengthen and expand distributor relationships.
• Realign sales teams.
• Reinvest in the business.
• Drive sustained, profitable growth.
• Host investor conference call and live webcast on August 6, 2026.

Key Dates

Recommendation

The filing is an amendment to correct a clerical error and reiterates previously provided financial results and guidance. While there are positive signs like improved margins and cash flow, the slight year-over-year revenue decline and the need for a 'Return-to-Growth Action Plan' suggest a period of stabilization rather than significant growth, warranting a 'hold' recommendation pending further execution of the plan.

Keywords

dental products, financial results, second quarter, net sales, earnings per share, adjusted EBITDA, cash flow, guidance